Literatur
-
1
Botré F.
Drugs of abuse and abuse of drugs in sportsmen: the role of in vitro models to study effects and mechanisms.
Toxicol In Vitro.
2003;
17
509-513
-
2
Chiara G Di, Acquas E, Tanda G, Cadoni C.
Drugs of abuse: biochemical surrogates of specific aspects of natural reward?.
Biochem Soc Symp.
1993;
59
65-81
-
3
Neiman J, Haapaniemi H M, Hilborn M.
Neurological complications of drug abuse: pathophysiological mechanisms.
Eur J Neurol.
2000;
7
595-606
-
4
Kreek M J.
Drug Addictions. Molecular and cellular endpoints.
Ann N Y Acad Sci.
2001;
937
27-46
-
5
González M I, Robinson M B.
Neurotransmitter transporters: why dance with so many partners?.
Curr Opin Pharmacol.
2004;
4
30-35
-
6
Kobayashi H, Suzuki T, Kamata R. et al .
Recent progress in the neurotoxicology of natural drugs associated with dependence or addiction, their endogenous agonists and receptors.
J Toxicol Sci.
1999;
24
1-16
-
7
Pert C B, Snyder S H.
Opiate receptor: demonstration in nervous tissue.
Science.
1973;
179
1011-1014
-
8
Devane W A, Dysarz 3rd
F A, Johnson M R. et al .
Determination and characterization of a cannabinoid receptor in rat brain.
Mol Pharmacol.
1988;
34
605-613
-
9
Matsuda L A, Lolait S J, Brownstein M J. et al .
Structure of a cannabinoid receptor and functional expression of cloned DNA (cDNA).
Nature.
1990;
346
561-564
-
10
Hughes J, Smith T W, Kosterlitz H W. et al .
Identification of two related pentapeptides from the brain with potent opiate agonist activity.
Nature.
1975;
258
577-580
-
11
Devane W A, Hanus L, Breuer A. et al .
Isolation and structure of a brain constituent that binds to the cannabinoid receptor.
Science.
1992;
258
1946-1949
-
12
Nutt D J.
Addiction: brain mechanisms and their treatment implications.
Lancet.
1996;
347
31-36
-
13
Nestler E J, Aghajanian G K.
Molecular and cellular basis of addiction.
Science.
1997;
278
58-63
-
14
Nestler E J.
Molecular basis of long-term plasticity underlying addiction.
Nat Rev Neurosci.
2001;
2
119-128
-
15
Wise R A.
Neurobiology of addiction.
Curr Opin Neurobiol.
1996;
6
243-251
-
16
Wise R A.
Drug-activation of brain reward pathways.
Drug Alcohol Depend.
1998;
51
13-22
-
17
Koob G F, Ahmed S H, Boutrel B. et al .
Neurobiological mechanisms in the transition from drug use to drug dependence.
Neurosci Biobehav Rev.
2004;
27
739-749
-
18
Amara S G, Sonders M S.
Neurotransmitter transporters as molecular targets for addictive drugs.
Drug Alcohol Depend.
1998;
51
87-96
-
19
Rothman R B, Baumann M H.
Monoamine transporters and psychostimulant drugs.
Eur J Pharmacol.
2003;
479
23-40
-
20
Liu Y, Krantz D E, Waites C, Edwards R H.
Membrane trafficking of neurotransmitter transporters in the regulation of synaptic transmission.
Trends Cell Biol.
1999;
9
356-363
-
21
Laakso A, Mohn A R, Gainetdinov R R, Caron M G.
Experimental genetic approaches to addiction.
Neuron.
2002;
36
213-228
-
22
Betz C, Mihalic D, Pinto M E, Raffa R B.
Could a common biochemical mechanism underlie addictions?.
J Clin Pharm Ther.
2000;
25
11-20
-
23
Pulvirenti L, Diana M.
Drug dependence as a disorder of neural plasticity: focus on dopamine and glutamate.
Rev Neurosci.
2001;
12
141-158
-
24
Saal D, Dong Y, Bonci A, Malenka R C.
Drugs of abuse and stress trigger a common synaptic adaptation in dopamine neurons.
Neuron.
2003;
37
557-582
-
25
Nakamichi N, Yoneda Y.
Transcription factors and drugs in the brain.
Jpn J Pharmacol.
2002;
89
337-348
-
26
Lüscher C, Nicoll R A, Malenka R C, Muller D.
Synaptic plasticity and dynamic modulation of the postsynaptic membrane.
Nature Neurosci.
2000;
3
545-550
-
27
Winder D G, Egli R E, Schramm N L, Matthews R T.
Synaptic plasticity in drug reward circuitry.
Curr Mol Med.
2002;
2
667-676
-
28
Wolf M E.
LTP may trigger addiction.
Mol Intervent.
2003;
3
248-252
-
29
Harlan R E, Garcia M M.
Drugs of abuse and immediate-early genes in the forebrain.
Mol Neurobiol.
1998;
16
221-267
-
30
Kauer J A.
Learning mechanisms in addiction: Synaptic plasticity in the ventral tegmental area as a result of exposure to drugs of abuse.
Annu Rev Physiol.
2004;
66
447-475
-
31
Levitt P.
Prenatal effects of drugs of abuse on brain development.
Drug Alcohol Depend.
1998;
51
109-125
-
32
Kosofsky B E, Hyman S E.
No time for complacency: the fetal brain on drugs.
J Comp Neurol.
2001;
435
259-262
-
33
Farber N B, Olney J W.
Drugs of abuse that cause developing neurons to commit suicide.
Dev Brain Res.
2003;
147
37-45
-
34
Greene C M, Goodman M H.
Neonatal abstinence syndrome: strategies for care of the drug-exposed infant.
Neonatal Netw.
2003;
22
15-25
-
35
Koob G F, Moal M Le.
Drug addiction, dysregulation of reward, and allostasis.
Neuropsychopharmacology.
2001;
24
97-129
-
36
Jacobs E H, Smit A B, Vries T J de, Schoffelmeer A NM.
Neuroadaptive effects of active versus passive drug administration in addiction research.
Trends Pharmacol Sci.
2003;
24
566-573
-
37
Kosten T R, O'Connor P G.
Management of drug and alcohol withdrawal.
New Engl J Med.
2003;
348
1786-1795
-
38
Lu L, Hope B T, Dempsey J. et al .
Central amygdala ERK signalling pathway is critical to incubation of cocaine craving.
Nature Neurosci.
2005;
8
212-219
-
39
Smith R F.
Animal models of periadolescent substance abuse.
Neurotoxicol Teratol.
2003;
25
291-301
-
40
Iacono W G, Malone S M, McGue M.
Substance use disorders, externalizing psychopathology, and P300 event-related potential amplitude.
Int J Psychopathol.
2003;
48
147-178
-
41
Little H J.
The contribution of electrophysiology to knowledge of the acute and chronic effects of ethanol.
Pharmacol Ther.
1999;
84
333-353
-
42
Mendelssohn A de, Kasper S, Tauscher J.
Neuroimaging bei Substanzabhängigkeit.
Nervenarzt.
2004;
75
651-662
-
43
Wilson S J, Sayette M A, Fiez J A.
Prefrontal responses to drug cues: a neurocognitive analysis.
Nature Neurosci.
2004;
7
211-214
-
44
Volkow N D, Fowler J S, Wang G J.
The addicted human brain viewed in the light of imaging studies: brain circuits and treatment strategies.
Neuropharmacology.
2004;
47
3-13
-
45
Sullivan E V, Pfefferbaum A.
Diffusion tensor imaging in normal aging and neuropsychiatric disorders.
Eur J Radiol.
2003;
45
244-255
-
46
Rosenbloom M, Sullivan E, Pfefferbaum A.
Using magnetic resonance imaging and diffusion tensor imaging to assess brain damage in alcoholics.
Alcohol Res Health.
2003;
27
146-152
-
47
Melichar J K, Hume S P, Williams T M. et al .
Using [11C]Diprenorphine to image opioid receptor occupancy by methadone in opioid addiction: clinical and preclinical studies.
J Pharmacol Exp Ther.
2005;
312
309-315
-
48
Kreek M J.
Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine.
Ann N Y Acad Sci.
2000;
909
186-216
-
49
Haasen C, Krausz M.
Myths versus evidence with respect to cocaine and crack: Learning from the US experience.
Eur Addict Res.
2001;
7
159-160
-
50
Emilien G, Maloteaux J M, Geurts M. et al .
Dopamine receptors - physiological understanding to therapeutic intervention potential.
Pharmacol Ther.
1999;
84
133-156
-
51
Self D W.
Regulation of drug-taking and -seeking behaviours by neuroadaptations in the mesolimbic dopamine system.
Neuropsychopharmacology.
2004;
47 (Suppl 1)
S242-S255
-
52
Salter M W.
D1 and NMDA receptors hook up: expanding on an emerging theme.
Trends Neurosci.
2003;
26
235-237
-
53
Richtand N M, Goldsmith R J, Nolan J E, Berger S P.
The D3 dopamine receptor and substance dependence.
J Addict Dis.
2001;
20
19-32
-
54
Noda Y, Nabeshima T.
Opiate physical dependence and N-methyl-D-aspartate receptors.
Eur J Pharmacol.
2004;
500
121-128
-
55
Siggins G R, Martin G, Roberto M. et al .
Glutamatergic transmission in opiate and alcohol dependence.
Ann N Y Acad Sci.
2003;
1003
196-211
-
56
Loftis J M, Janowsky A.
Cocaine treatment- and withdrawal-induced alterations in the expression and serine phosphorylation of the NR1 NMDA receptor subunit.
Psychopharmacology.
2002;
164
349-359
-
57
Loftis J M, Janowsky A.
The N-methyl-D-aspartate receptor subunit NR2B: localization, functional properties, regulation, and clinical implications.
Pharmacol Ther.
2003;
97
55-85
-
58
Kalivas P W.
Glutamate systems in cocaine addiction.
Curr Opin Pharmacol.
2004;
4
23-29
-
59
Carlezon Jr W A, Nestler E J.
Elevated levels of GluR1 in the midbrain: a trigger for sensitization to drugs of abuse?.
Trends Neurosci.
2002;
25
610-615
-
60
Kenny P J, Markou A.
The ups and downs of addiction: role of metabotropic glutamate receptors.
Trends Pharmacol Sci.
2004;
25
265-272
-
61
Kumar S, Fleming R L, Morrow A L.
Ethanol regulation of gamma-aminobutyric acid A receptors: genomic and nongenomic mechanisms.
Pharmacol Ther.
2004;
101
211-226
-
62
Cousins M S, Roberts D C, Witt H de.
GABA(B) receptor agonists for the treatment of drug addiction: a review of recent findings.
Drug Alcohol Depend.
2002;
65
209-220
-
63
Dani J A.
Overview of nicotinic receptors and their roles in the central nervous system.
Biol Psychiatry.
2001;
49
166-174
-
64
Homberg J R, Raaso H S, Schoffelmeer A NM, Vries T J de.
Individual differences in sensitivity to factors provoking reinstatement of cocaine-seeking behavior.
Behav Brain Res.
2004;
152
157-161
-
65
Zhang L C, Buccafusco J J.
Prevention of morphine-induced muscarinic (M2) receptor adaptation suppresses the expression of withdrawal symptoms.
Brain Res.
1998;
803
114-121
-
66
Fink-Jensen A, Fedorova I, Wörtwein G. et al .
Role for M5 muscarinic acetylcholine receptors in cocaine addicition.
J Neurosci Res.
2003;
74
91-96
-
67
Roth B L, Willins D L, Kroeze W K.
G protein-coupled receptor (GPCR) trafficking in the central nervous system: relevance for drugs of abuse.
Drug Alcohol Depend.
1998;
51
73-85
-
68
Grant K A.
The role of 5-HT3 receptors in drug dependence.
Drug Alcohol Depend.
1995;
38
155-171
-
69
Daly J W, Fredholm B B.
Caffeine - an atypical drug of dependence.
Drug Alcohol Depend.
1998;
51
199-206
-
70
Hack S P, Christie M J.
Adaptations in adenosine signaling in drug dependence: therapeutic implications.
Crit Rev Neurobiol.
2003;
15
235-274
-
71
Moreau J L, Huber G.
Central adenosine A2A receptors: an overview.
Brain Res Rev.
1999;
31
65-82
-
72
Baraldi P G, Cacciari B, Romagnoli R. et al .
A3 adenosine receptor ligands: history and perspectives.
Med Res Rev.
2000;
20
103-128
-
73
Reis D J, Regunathan S.
Is agmatine a novel neurotransmitter in brain?.
Trends Pharmacol Sci.
2000;
21
187-193
-
74
García-Sevilla J A, Escribá P V, Guimón J.
Imidazoline receptors and human brain disorders.
Ann N Y Acad Sci.
1999;
881
392-409
-
75
Howlett A C, Breivogel C S, Childers S R. et al .
Cannabinoid physiology and pharmacology: 30 years of progress.
Neuropharmacology.
2004;
47
345-358
-
76
Iversen L.
Cannabis and the brain.
Brain.
2003;
126
1252-1270
-
77
Ralevic V.
Cannabinoid modulation of peripheral autonomic and sensory neurotransmission.
Eur J Pharmacol.
2003;
472
1-21
-
78
Nestler E J.
Molecular mechanisms of drug addiction.
Neuropharmacology.
2004;
47 (Suppl 1)
S24-S32
-
79
Isola R, Zhang H, Duchemin A M. et al .
Met-enkephalin and preproenkephalin mRNA changes in the striatum of the nicotine abstinence mouse.
Neurosci Lett.
2002;
325
67-71
-
80
Plotkin S R, Banks W A, Cohn C S, Kastin A J.
Withdrawal from alcohol in withdrawal seizure-prone and -resistant mice: evidence for enkephalin resistance.
Pharmacol Biochem Behav.
2001;
68
379-387
-
81
Nylander I, Vlaskovska M, Terenius L.
The effects of morphine treatment and morphine withdrawal on the dynorphin and enkephalin systems in Sprague-Dawley rats.
Psychopharmacology.
1995;
118
391-400
-
82
Akil H, Owens C, Gutstein H. et al .
Endogenous opioids: overview and current issues.
Drug Alcohol Depend.
1998;
51
127-140
-
83
Kreek M J.
Opioid receptors: some perspectives from early studies of their role in normal physiology, stress responsivity, and in specific addictive diseases.
Neurochem Res.
1996;
21
1469-1488
-
84
Ciccocioppo R, Angeletti S, Panocka I, Massi M.
Nociceptin/orphanin FQ and drugs of abuse.
Peptides.
2000;
21
1071-1080
-
85
Meunier J C.
Nociceptin/orphanin FQ and the opioid receptor-like ORL1 receptor.
Eur J Pharmacol.
1997;
340
1-15
-
86
Hanson G R, Singh N, Merchant K. et al .
Responses of limbic and extrapyramidal neurotensin systems to stimulants of abuse. Involvement of dopaminergic mechanisms.
Ann N Y Acad Sci.
1992;
668
165-172
-
87
Richelson E, Boules M, Frederickson P.
Neurotensin agonists: possible drugs for treatment of psychostimulant abuse.
Life Sci.
2003;
73
679-690
-
88
Sarnyai Z, Kovacs G L.
Role of oxytocin in the neuroadaptation to drugs of abuse.
Psychoneuroendocrinology.
1994;
19
85-117
-
89
Kovács G L, Darnyai Z, Szabó G.
Oxytocin and addiction: a review.
Psychoneuroendocrinology.
1998;
23
945-962
-
90
Gimpl G, Fahrenholz F.
The oxytocin receptor system: structure, function, and regulation.
Physiol Rev.
2001;
81
629-683
-
91
Zingg H H, Laporte S A.
The oxytocin receptor.
Trends Endocrinol Metab.
2003;
14
222-227
-
92
Zachariou V, Thome J, Parikh K, Picciotto M R.
Upregulation of galanin binding sites and GalR1 mRNA levels in the mouse locus coeruleus following chronic morphine treatments and precipitated morphine withdrawal.
Neuropsychopharmacology.
2000;
23
127-137
-
93
Zachariou V, Brunzell D H, Hawes J. et al .
The neuropeptide galanin modulates behavioural and neurochemical signs of opiate withdrawal.
Proc Natl Acad Sci U.S.A..
2003;
100
9028-9033
-
94
Takahashi L K.
Role of CRF(1) and CRF(2) receptors in fear and anxiety.
Neurosci Biobehav Rev.
2001;
25
627-636
-
95
Roumy M, Garnier M, Zajac J M.
Neuropeptide FF receptors 1 and 2 exert an anti-opioid activity in acutely dissociated rat dorsal raphe and periventricular hypothalamic neurones.
Neurosci Lett.
2003;
348
159-162
-
96
Gouarderes C, Puget A, Zajac J M. et al .
Neuropeptide Y (NPY) in stress and alcohol dependence.
Rev Neurosci.
2002;
13
85-94
-
97
Nystedt J M, Lemberg K, Lintunen M. et al .
Pain- and morphine-associated transcriptional regulation of neuropeptide FF and the G-protein-coupled NPFF2 receptor gene.
Neurobiol Dis.
2004;
16
254-262
-
98
Blomqvist A G, Herzog H.
Y-receptors subtypes - how many more?.
Trends Neurosci.
1997;
20
294-298
-
99
Chronwall B M, Zukowska Z.
Neuropeptide Y, ubiquitous and elusive.
Peptides.
2004;
25
359-363
-
100
Heilig M, Thorsell A.
Neuropeptide Y (NPY) in stress and alcohol dependence.
Rev Neurosci.
2002;
13
85-94
Dr. med. Stephan Rüegg
Abt. für Klinische Neurophysiologie · Neurologische Klinik · Universitätsspital
Petersgraben 4
4031 Basel · Schweiz
eMail: srueegg@uhbs.ch
